Toxic skin effects common with EGFR-TKI use in NSCLC

Toxic skin effects common with EGFR-TKI use in NSCLC

(HealthDay)—For patients with non-small-cell lung cancer, treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is associated with skin toxic effects, according to a research letter study published online Dec. 10 in JAMA Dermatology.

Kai-Lung Chen, M.D., from the National Taiwan University Hospital in Taipei, and colleagues conducted a to compare the incidences and severities of the four types of skin toxic effects for three different EGFR-TKIs. Data were included for 146 patients with meeting the inclusion criteria; of these, 61, 117, and 93 had ever received gefitinib, erlotinib, and afatinib, respectively.

The researchers found that the incidence of acneiform eruption was highest, followed by pruritus and xerosis (67.2 to 76.3 percent and 47.5 to 63.4 percent, respectively). Paronychia incidence was the lowest and varied significantly among the EGFR-TKIs: 9.8, 12.8, and 39.8 for gefitinib, erlotinib, and afatinib, respectively (P < 0.001). For patients with treatment courses extending at least 180 days, afatinib therapy correlated with earlier paronychia onset and with more dermatologic visits within the first 180 days for any skin toxic effects.

"Aggressive dermatologic care for receiving EGFR-TKIs should be mandatory," the authors write.

One author disclosed financial ties to the pharmaceutical industry.


Explore further

Lung cancer patients gain access to new treatment for fourth time in two months

More information: Full Text (subscription or payment may be required)
Journal information: JAMA Dermatology

Copyright © 2015 HealthDay. All rights reserved.

Citation: Toxic skin effects common with EGFR-TKI use in NSCLC (2015, December 11) retrieved 19 August 2019 from https://medicalxpress.com/news/2015-12-toxic-skin-effects-common-egfr-tki.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more